SEC Form 4 · accession 0001140361-18-016271
BIOMARIN PHARMACEUTICAL INC · BMRN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jeffrey Robert Ajer
Officer — EVP, Chief Commercial Officer
Period of report
Mar 29, 2018
Accepted (ET)
Mar 30, 2018 · 8:03 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001048477
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Mar 29, 2018 | S | 1,537 | $79.69 | D | 55,033 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Trade made pursuant to a 10b5-1 plan executed on September 6, 2017.